|

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

RECRUITINGSponsored by Eisai Co., Ltd.
Actively Recruiting
SponsorEisai Co., Ltd.
Started2024-02-14
Est. completion2027-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06322667

Summary

The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* All participants who are treated with lecanemab in routine clinical practice

Exclusion Criteria:

* None

Conditions1

Alzheimer's Disease

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.